A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours

Trial Profile

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merck KGaA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 12 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top